Jun 2026 (Q2 FY26) — Jul 30, 2026
Amneal Q2 FY26 — Strong Performance, Raised Outlook, and Strategic Transformation
Read the full callAmneal (AMRX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Amneal earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 796 | +9.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 16.3 | +0.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 57.7 | +157.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
17 of 25 judged targets kept · 34 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Adjusted EBITDA | $720 million to $760 million | Dec 2025 | Also, we're raising our adjusted EBITDA guidance by $10 million between $750 million and $780 million, reflecting strong revenues and higher gross margin. | Revised Up |
| Adjusted gross margin | over 44% | Dec 2025 | Our second quarter adjusted gross margin was strong at 46.2%, up 60 basis points year-over-year, reflecting favorable mix and continued operating efficiencies. | On Track |
8 of Amneal Pharmaceuticals, Inc.'s 59 targets were missed. See which ones, and which are quietly gone. The 2 above are the free sample; 57 more targets are in the full ledger.
Claimed
- Total net revenue grew 10% year-over-year to $796 million.
- Adjusted EBITDA increased 12% year-over-year to $206 million.
- Adjusted EPS rose 20% year-over-year to $0.30.
- Full-year 2026 revenue outlook raised by $50 million to $3.1 billion - $3.2 billion.
- Full-year 2026 adjusted EBITDA guidance raised by $10 million to $750 million - $780 million.
Qualified
- AvKARE revenue decreased 4% year-over-year to $157 million, due to the low-margin distribution business.
- India facility flood is estimated to have a $20 million negative impact on full-year 2026 guidance.
Price
$19.36 +0.94% · +$0.18
Performance +95.2% 1Y
1Y: $9.92 on 17 Oct 2025 → $19.36. High $20.5 (28 Sept 2026), low $9.92 (17 Oct 2025).
- Previous close
- $19.18
- 52-week range
- $10 – $20.5
- One year
- +89.06%
Overview
- Symbol
- AMRX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
17 of 25 judged targets kept · 34 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Adjusted EBITDA | $720 million to $760 million | Dec 2025 | Also, we're raising our adjusted EBITDA guidance by $10 million between $750 million and $780 million, reflecting strong revenues and higher gross margin. | Revised Up |
| Adjusted gross margin | over 44% | Dec 2025 | Our second quarter adjusted gross margin was strong at 46.2%, up 60 basis points year-over-year, reflecting favorable mix and continued operating efficiencies. | On Track |
Claimed
- Total net revenue grew 10% year-over-year to $796 million.
- Adjusted EBITDA increased 12% year-over-year to $206 million.
- Adjusted EPS rose 20% year-over-year to $0.30.
- Full-year 2026 revenue outlook raised by $50 million to $3.1 billion - $3.2 billion.
- Full-year 2026 adjusted EBITDA guidance raised by $10 million to $750 million - $780 million.
Qualified
- AvKARE revenue decreased 4% year-over-year to $157 million, due to the low-margin distribution business.
- India facility flood is estimated to have a $20 million negative impact on full-year 2026 guidance.
The full ledger
Open Amneal Pharmaceuticals, Inc.’s full ledger
A free account opens 5 company ledgers a month. All 59 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — Apr 22, 2026
Amneal Q1 FY26 — Kashiv BioSciences Acquisition and Strong Q1 Performance
Read the full callDec 2025 (Q4 FY25) — Feb 27, 2026
Amneal Pharmaceuticals Q4 FY25 — Strong Growth and Strategic Portfolio Expansion
Read the full callEvery analysed call
Amneal earnings calls (AMRX)
Financials
What the filings say
Net profit, year on year: +157% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 702 | 731 | 695 | 725 | 785 | 814 | 723 | 796 |
| Operating profit | 89 | 76 | 100 | 111 | 70 | 112 | 142 | 130 |
| Operating margin | 12.6% | 10.4% | 14.4% | 15.4% | 9.0% | 13.8% | 19.6% | 16.3% |
| Other income | -73 | -91 | -63 | -60 | -76 | -57 | -62 | -59 |
| Profit before tax | 15 | -15 | 37 | 52 | -5 | 55 | 80 | 71 |
| Tax rate | 23.8% | −35.4% | 34.3% | 31.1% | 447.2% | 10.3% | 2.7% | 1.9% |
| Net profit | -0 | -31 | 12 | 22 | 2 | 35 | 62 | 58 |
| EPS ($ per share) | 0 | — | 0.04 | 0.07 | 0.01 | — | 0.20 | 0.18 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | -21 | -378 | -287 | -276 | -406 | -490 | -607 | -535 |
| Total liabilities | 3,456 | 3,319 | 3,661 | 3,573 | 3,615 | 3,453 | 3,611 | 3,750 |
| Fixed assets | 544 | 478 | 478 | 514 | 470 | 448 | 425 | 443 |
| Total assets | 4,353 | 3,666 | 4,006 | 3,940 | 3,799 | 3,473 | 3,501 | 3,678 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 250 | 2 | 379 | 242 | 65 | 346 | 295 | 340 |
| Cash from investing | -396 | -20 | -318 | -194 | -174 | -69 | -63 | -112 |
| Cash from financing | 288 | -46 | 132 | -138 | -107 | -213 | -212 | -32 |
| Net cash flow | 141 | -66 | 194 | -90 | -222 | 64 | 19 | 195 |
| Capital expenditure | -83 | -47 | -56 | -48 | -46 | -43 | -52 | -70 |
| Free cash flow | 167 | -45 | 323 | 194 | 19 | 302 | 243 | 270 |
AMRX revenue by segment
Affordable Medicines grew from 54% to 59% of revenue over the last two years.
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Affordable Medicines | — | — | 60% | 60% | 59% | 54% | 59% | 62% | +13.0% |
| Av KARE | 23% | 23% | 25% | 23% | 25% | 26% | 23% | 20% | -3.7% |
| Amneal Specialty Pharma | 16% | — | 16% | 18% | 16% | — | 18% | 19% | +16.6% |
| Specialty | 16% | 17% | 16% | 18% | 16% | 21% | — | 19% | +16.6% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q4 FY2025 · share of revenue
- US 227% ↑ 128 pt
As AMRX cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
79 filings between Nov 12, 2025 and Sep 17, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$9.82M
7 sales by 5 insiders
Compensation
not trading decisions- 4
- Award — granted as compensation
- 38
- Option exercise — converted options into shares
- 26
- Tax withheld — shares kept back by the company to cover tax
Also filed: 4 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Shah Nikita | — | $4.14M | Aug 12, 2026 |
| Daly Jason B. | — | $3.77M | Aug 12, 2026 |
| Kiely John | — | $882.0K | Aug 13, 2026 |
| Nark Ted C | — | $586.0K | Nov 17, 2025 |
| Autor Deborah M. | — | $450.6K | May 11, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 17, 2026 | BUCHI J KEVIN Director | Gift | 20,445 | $0 |
| Sep 11, 2026 | BUCHI J KEVIN Director | Option exercise | 20,445 | $295.4K |
| Sep 1, 2026 | BOYER ANDREW S Executive Vice President | Gift | 80,000 | $0 |
| Aug 21, 2026 | BOYER ANDREW S Executive Vice President | Gift | 152,426 | $0 |
| Aug 13, 2026 | Kiely John Director | Gift | 10,000 | $0 |
| Aug 13, 2026 | Kiely John Director | Sale | 50,000 | $882.0K |
| Aug 12, 2026 | Daly Jason B. EVP, Chief Legal Officer | Sale | 210,000 | $3.65M |
| Aug 12, 2026 | Shah Nikita Executive Vice President | Sale | 146,403 | $2.56M |
| Aug 11, 2026 | Daly Jason B. EVP, Chief Legal Officer | Sale | 6,613 | $117.1K |
| Aug 11, 2026 | BUCHI J KEVIN Director | Option exercise | 168,573 | $2.90M |
| Aug 10, 2026 | Patel Gautam Director | Award | 283,632 | — |
| Aug 10, 2026 | Patel Tushar Bhikhubhai 10% owner | Award | 12,763,469 | — |
| Aug 10, 2026 | Patel Chintu Co-CEO | Award | 6,381,734 | — |
| Aug 10, 2026 | Patel Chirag K. President & Co-CEO | Award | 6,381,734 | — |
| May 11, 2026 | Autor Deborah M. Director | Sale | 34,819 | $450.6K |
| May 7, 2026 | Autor Deborah M. Director | Option exercise | 34,819 | — |
| May 7, 2026 | George Jeffrey P. Director | Option exercise | 34,819 | — |
| May 7, 2026 | MEISTER PAUL M Director | Option exercise | 48,747 | — |
| May 7, 2026 | BUCHI J KEVIN Director | Option exercise | 34,819 | — |
| May 7, 2026 | Patel Gautam Director | Option exercise | 34,819 | — |
| May 7, 2026 | Yanai Shlomo Director | Option exercise | 34,819 | — |
| May 7, 2026 | Kiely John Director | Option exercise | 34,819 | — |
| May 7, 2026 | Nark Ted C Director | Option exercise | 34,819 | — |
| Mar 4, 2026 | BOYER ANDREW S Executive Vice President | Option exercise | 38,195 | — |
| Mar 4, 2026 | Shah Nikita Executive Vice President | Option exercise | 35,880 | — |
| Mar 4, 2026 | Konidaris Tasos Executive Vice President & CFO | Tax withheld | 22,035 | $293.1K |
| Mar 4, 2026 | Konidaris Tasos Executive Vice President & CFO | Option exercise | 43,982 | — |
| Mar 4, 2026 | BOYER ANDREW S Executive Vice President | Tax withheld | 19,136 | $254.5K |
| Mar 4, 2026 | Patel Chintu Co-CEO | Option exercise | 92,593 | — |
| Mar 4, 2026 | Shah Nikita Executive Vice President | Tax withheld | 17,976 | $239.1K |
| Mar 4, 2026 | Patel Chirag K. President & Co-CEO | Tax withheld | 37,825 | $503.1K |
| Mar 4, 2026 | Patel Chintu Co-CEO | Tax withheld | 28,983 | $385.5K |
| Mar 4, 2026 | Daly Jason B. EVP, Chief Legal Officer | Option exercise | 35,880 | — |
| Mar 4, 2026 | Daly Jason B. EVP, Chief Legal Officer | Tax withheld | 15,580 | $207.2K |
| Mar 4, 2026 | Patel Chirag K. President & Co-CEO | Option exercise | 92,593 | — |
| Mar 3, 2026 | BOYER ANDREW S Executive Vice President | Option exercise | 39,252 | — |
| Mar 3, 2026 | Shah Nikita Executive Vice President | Tax withheld | 183,853 | $2.45M |
| Mar 3, 2026 | Shah Nikita Executive Vice President | Option exercise | 366,972 | — |
| Mar 3, 2026 | Shah Nikita Executive Vice President | Tax withheld | 11,796 | $157.0K |
| Mar 3, 2026 | Konidaris Tasos Executive Vice President & CFO | Tax withheld | 229,817 | $3.06M |
| Mar 3, 2026 | Shah Nikita Executive Vice President | Option exercise | 23,544 | — |
| Mar 3, 2026 | Shah Nikita Executive Vice President | Tax withheld | 22,982 | $305.9K |
| Mar 3, 2026 | Konidaris Tasos Executive Vice President & CFO | Option exercise | 458,716 | — |
| Mar 3, 2026 | Konidaris Tasos Executive Vice President & CFO | Tax withheld | 14,298 | $190.3K |
| Mar 3, 2026 | Konidaris Tasos Executive Vice President & CFO | Option exercise | 28,538 | — |
| Mar 3, 2026 | Konidaris Tasos Executive Vice President & CFO | Tax withheld | 24,251 | $322.8K |
| Mar 3, 2026 | Konidaris Tasos Executive Vice President & CFO | Option exercise | 57,339 | — |
| Mar 3, 2026 | Konidaris Tasos Executive Vice President & CFO | Tax withheld | 16,182 | $215.4K |
| Mar 3, 2026 | Konidaris Tasos Executive Vice President & CFO | Option exercise | 45,290 | — |
| Mar 3, 2026 | Shah Nikita Executive Vice President | Option exercise | 45,871 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Amneal Pharmaceuticals, Inc.
Free account. Everything above stays public.
Write why you follow Amneal Pharmaceuticals, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading